Sign in

    Amgen Inc (AMGN)

    Q1 2024 Earnings Summary

    Reported on Jan 10, 2025 (After Market Close)
    Pre-Earnings Price$278.39Last close (May 2, 2024)
    Post-Earnings Price$313.39Open (May 3, 2024)
    Price Change
    $35.00(+12.57%)

    What went well

    • Amgen is rapidly advancing MariTide, a promising obesity treatment, and plans to move swiftly to Phase III studies due to positive Phase II results and recognizing a huge unmet need in the marketplace. ,
    • Amgen's deep expertise in CD19-directed therapeutics, inflammation, and autoimmunity positions it to capitalize on new opportunities, inspired by recent developments in systemic sclerosis and refractory rheumatoid arthritis treatments.
    • Amgen is leveraging its experience in developing CD3 bispecifics to advance solid tumor targeting T-cell engaging therapies, expecting future progress on medicines like AMG 651 and tarlatimab.

    What went wrong

    • Executives were unable to provide specific timelines or details on the initiation of Phase III studies for MariTide, their obesity candidate, indicating potential uncertainties in the development timeline.
    • Lack of updates on AMG 651, their EGFR-CD3 bispecific program, with executives stating they have no news to share, possibly signaling slow progress or challenges in the development.
    • When questioned about safety metrics for MariTide, executives avoided providing detailed information, which may raise concerns about safety issues in the ongoing study.

    Q&A Summary

    1. MariTide Differentiation
      Q: What differentiates MariTide from competitors?
      A: Management highlighted MariTide's broad and differentiated profile , with potential advantages in efficacy, tolerability, and dosing interval. They are confident in its ability to address unmet medical needs and provide access for millions of patients , positioning it as a competitive product in the market.

    2. Manufacturing Capacity for MariTide
      Q: Can you meet manufacturing demands for MariTide?
      A: The company is confident in supplying millions of patients with MariTide , leveraging their experience in biotherapeutic manufacturing. They emphasized their commitment to supplying every patient, every time , noting that monthly or less frequent dosing reduces the need for injection devices compared to weekly therapies.

    3. Tarlatamab Launch Preparation
      Q: How are you preparing for Tarlatamab's launch?
      A: Amgen is well-prepared for Tarlatamab's potential approval , with trained field personnel and plans for broad access upon approval. They view it as a major advance in small cell lung cancer treatment and have initiated three Phase III studies to move it into earlier therapy lines.

    4. MariTide Expansion Plans
      Q: Will MariTide target conditions beyond obesity and diabetes?
      A: Management is planning a broad Phase III program to address unmet needs in obesity and related conditions , continuing to develop MariTide as intended.

    5. TEZSPIRE in COPD
      Q: What's TEZSPIRE's potential role in COPD?
      A: TEZSPIRE showed clinically meaningful activity in a Phase II COPD trial , with full data to be presented at the American Thoracic Society Meeting. The company recognizes COPD's heterogeneity and is interested in further development due to the drug's mechanism targeting type 2 inflammation.

    6. Rocatinlimab Differentiation
      Q: How will Rocatinlimab compete in atopic dermatitis?
      A: Rocatinlimab aims for a competitive profile with strong efficacy and excellent patient experience. The Phase III HORIZON study involves 726 patients , and management believes it can be effectively positioned against treatments like Dupixent.

    7. MariTide Phase III Timing
      Q: When will MariTide's Phase III start, and how will you accelerate it?
      A: The company plans to complete Phase II and work swiftly with regulators on the Phase III program , moving as rapidly as possible to address the huge unmet need.

    8. BLINCYTO in Autoimmune Disorders
      Q: Any plans for BLINCYTO in autoimmune diseases?
      A: Management is well-organized to explore BLINCYTO's potential in autoimmune disorders , finding recent findings inspiring and planning to report more in the future.

    9. AMG 651 Oncology Development
      Q: Any updates on AMG 651's development in oncology?
      A: The company continues to study AMG 651 and other solid tumor targeting bispecific T-cell engagers , with no new data yet but confidence inspired by tarlatamab's progress.

    Related Publications